该站点未添加描述description...

该站点未添加描述description...

适新科技（苏州）有限公司成立于1996年12月31日，注册资本7704.38万美元，隶属于苏州安洁科技股份有限公司。集团在新加坡、马来西亚、泰国和中国设有工厂，主要从事高精密金属零部件研发和生产。

该站点未添加描述description...

湖南巨智慧科技有限公司成立于2018年，致力于为中小微企业、创业者提供资金、技术、人才、知识产权、政策、项目、管理一站式服务的科技型现代服务企业。

欣欣广东旅游网提供广东旅行社发布的旅游线路、广东旅游景点介绍、广东旅游攻略、广东订房、订票、导游和租车等出行指南及旅游服务●欣欣旅游网CNCN.com

浙江多乐缝纫机有限公司

拉卡拉pos机是拉卡拉支付集团研发的无线pos终端，拉卡拉POS机线上授权体验中心官网含有个人4G电签pos机、商家智能pos机等众多产品，不仅产品力强，口碑好，售后有保障，且拉卡拉是唯一上市的支付公司（股票代码SZ300773）。

重庆移通学院是全国十佳优秀独立学院！中国最具品牌价值独立学院！西部信息产业国际化人才的摇篮！

河北力乐管材有限公司主要为客户提供市政给水管道、塑料管材管件、PVC-O管材、PVC-U给水管道、高抗冲PVC-M管道、PVC-U井管、PE给水管道、PE双壁波纹管道等产品。

WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity，foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.

FreeHTMLTemplates